Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Following verbal and written information about the trial, subject must provide informed consent documented by signing the Informed Consent Form (ICF) prior to any trial related procedures~2. Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm² treatment area on the face or scalp~Exclusion Criteria:~1. Location of the selected treatment area:~* on the periorbital skin~* on the perioral skin/around the nostrils~* within 5 cm of an incompletely healed wound~* within 10 cm of a suspected BCC or SCC or other neoplasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A (Type: ACTIVE_COMPARATOR): Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
- Treatment Group B (Type: ACTIVE_COMPARATOR): Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).